Soluble intercellular adhesion molecule-1 and interleukin-6 levels reflect endothelial dysfunction in patients with primary hypercholesterolaemia treated with atorvastatin

Statins as antiinflammatory and immunomodulatory agents: A future in rheumatologic therapy?

“…Perhaps of greater significance is that a number of ex vivo human studies showed that statins downregulate the soluble concentration of these molecules. Shed (soluble) adhesion molecules are well-known markers for atherosclerotic disease (36)(37)(38), and several studies indicated that statins down-regulate circulating soluble ICAM-1, vascular cell adhesion molecule 1 (39)(40)(41), and E-and P-selectin (42,43). However, not all studies that examined the effects of statins on the soluble levels of these molecules have replicated these findings (44,45).…”

“…In separate, randomized prospective studies of patients with hypercholesterolemia and hypertension, treatment with simvastatin resulted in decreased circulating IL-1␤, and IL-1␤ production by isolated PBMCs, respectively (82,83). Both atorvastatin and simvastatin significantly decrease levels of circulating IL-6 and TNF␣, in addition to IL-1␤, in patients with hypercholesterolemia (39,41,59,84). Carotid plaques resected from patients taking statins contain significantly lower concentrations of IL-6 (P ϭ 396 ABELES AND PILLINGER 0.0005), suggesting that statins do, indeed, alter local inflammation in atherosclerotic lesions (85).…”

Plasma Pentraxin 3 is a More Potent Predictor of Endothelial Dysfunction than High-Sensitive C-Reactive Protein

“…[3][4][5] An infl ammatory response represents the key piece of evidence leading to endothelial dysfunction and the subsequent formation of atheromatous plaques. 1,6) C-reactive protein (CRP), a member of the pentraxin family, is the most well-established infl ammation marker and provides independent prognostic information in relation to various coronary heart diseases. 7) CRP levels have been reported to be inversely correlated with endothelial vasoreactivity.…”

Assessment of endothelial function in the patient with erectile dysfunction: an opportunity for the urologist

“…41,42 However, one study found that ADMA production was not correlated to decline of endothelial function with aging. 43 Inflammatory markers, such as interleukin-6 (IL-6), [44][45][46] Tumor necrosis factor-a (TNF-a) 45 or C-reactive protein (CRP) 46 have all been associated with impaired endothelial function, cardiovascular events and with ED. 47,48 Elevated CRP levels have also been found to significantly correlate with vascular ED as measured by penile Doppler.…”

“…47,48 Elevated CRP levels have also been found to significantly correlate with vascular ED as measured by penile Doppler. 49 Finally, markers of cellular adhesion, such as E-selectin, 50 intercellular adhesion molecule-1 Assessment of endothelial function in men with ED R Tamler and N Bar-Chama (ICAM-1) 44,51 or vascular cell adhesion molecule-1 (VCAM-1) 46 and thrombogenesis, such as von Willebrand factor (vWF) 52 or plasminogen-activator inhibitor type-1 (PAI-1) 53 have also been associated with endothelial dysfunction and increased risk of CAD. 54 This underlines the importance of inflammation and cellular adhesion in early atherosclerosis, 55 but-with the exception of CRP-so far has not resulted in increased clinical usability.…”